Drug sales for diabetes drug Jardiance may be going up in a few weeks as two top medical groups work to implement new guidelines for diabetes treatment.
The Food and Drug Administration recently decided to expand the health benefits for diabetes drug Jardiance, according to Reuters. The expansion will include preventing fatal heart attacks and strokes in type-2 diabetics.
The American Diabetes Association and the American Association of Clinical Endocrinologists are working on the new guidelines.
Jardiance is given to lower blood sugar in adults suffering from type-2 diabetes. There are more than 3 millions cases of the disease each year, according to Mayo Clinic.
You May Also Like
For patients with type-2 diabetes, the body has a hard time processing insulin. Over time, according to the American Diabetes Association, the body becomes incapable of producing enough insulin to maintain normal blood sugar levels.
Jardiance was approved for treating type-2 diabetes about two years ago. Physicians typically prescribed Jardiance when the blood sugar can’t be controlled by metformin alone, Reuters reported.
According to Eli Lilly, which manufactures Jardiance, the drug is the only diabetes medication with significant reduction in cardiovascular risk and cardiovascular death.
The drug also showed a 32 percent reduction in all-cause mortality and 35 percent reduction in hospitalization for heart failure.
You May Also Like
“These results are both novel and exciting for the millions of people living with type 2 diabetes at risk for cardiovascular disease,” said Bernard Zinman, lead investigator of the trial. “Addressing the burden of cardiovascular events, including death, is at the core of diabetes care, and until now no single diabetes medication has been associated with a reduction in mortality.”
